



11-14-08
USPTO
RECEIVED
DIVISION

DAC / Box M \$
JHEW

2008 NOV 18 PM 4:27

Attorney Docket No. S2071-701642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 24 2008

OFFICE OF PETITIONS

Applicant : Michael W. Heartlein et al. Conf. No. : 2793
Serial No. : 09/753,385
Filed : January 3, 2001
Patent No.: 6,858,578
Issue Date: February 22, 2005
Title : CHIMERIC PROTEINS FOR USE IN TRANSPORT OF A SELECTED
SUBSTANCE INTO CELLS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

Sir:

Transmitted herewith are the following documents in connection with the above-identified patent application:


- ☒ [X] Correction Under 37 CFR 1.28(c) (2 pgs.);
- ☒ [X] Notification of Loss of Entitlement to Small Entity Status Under 37 CFR 1.27(g) (1 pg.); and
- ☒ [X] Return Receipt Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 395-7000.

The Commissioner is hereby authorized to charge the amount of \$515.00 for the deficiency of the Maintenance fee due at 3.5 years to Deposit Account No. 50/2762, Ref. No. S2071-701642. A duplicate copy of this transmittal is enclosed.

Respectfully submitted,

By:


Natalie A. Lissy, Reg. No. 59,681
LOWRIE, LANDO & ANASTASI, LLP
One Main Street
Cambridge, Massachusetts 02142
United States of America
Telephone: 617-395-7000
Facsimile: 617-395-7070

11/20/2008 DALLEN 00000029 502762 6858578
01 FC:1559 515.00 DA

Docket No.: S2071-701642
Date: November 13, 2008



Attorney Docket No. S2071-701642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 24 2008

OFFICE OF PETITIONS

Applicant : Michael W. Heartlein et al. Conf. No. : 2793
Serial No. : 09/753,385
Filed : January 3, 2001
Patent No.: 6,858,578
Issue Date: February 22, 2005
Title : CHIMERIC PROTEINS FOR USE IN TRANSPORT OF A SELECTED
SUBSTANCE INTO CELLS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

Sir:


Transmitted herewith are the following documents in connection with the above-identified patent application:

- ☒ [X] Correction Under 37 CFR 1.28(c) (2 pgs.);
- ☒ [X] Notification of Loss of Entitlement to Small Entity Status Under 37 CFR 1.27(g) (1 pg.); and
- ☒ [X] Return Receipt Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 395-7000.

The Commissioner is hereby authorized to charge the amount of \$515.00 for the deficiency of the Maintenance fee due at 3.5 years to Deposit Account No. 50/2762, Ref. No. S2071-701642.
A duplicate copy of this transmittal is enclosed.

Respectfully submitted,

By: 
Natalie A. Lissy, Reg. No. 59,681
LOWRIE, LANDO & ANASTASI, LLP
One Main Street
Cambridge, Massachusetts 02142
United States of America
Telephone: 617-395-7000
Facsimile: 617-395-7070

Docket No.: S2071-701642
Date: November 13, 2008



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 24 2008

OFFICE OF PATENT & TRADEMARK

Applicant : Michael W. Heartlein et al. Conf. No. : 2793
Serial No. : 09/753,385
Filed : January 3, 2001
Patent No.: 6,858,578
Issue Date: February 22, 2005
Title : CHIMERIC PROTEINS FOR USE IN TRANSPORT OF A SELECTED
SUBSTANCE INTO CELLS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CORRECTION UNDER 37 C.F.R. § 1.28(c)

This application was filed on January 3, 2001 and claimed small entity status. Applicants' small entity status was confirmed upon payment of the issue fee December 27, 2004. On August 22, 2008, Applicants in good faith paid the Maintenance fee due at three and a half years as a small entity.

Under 37 C.F.R. § 1.28(c), Applicants submit that the small entity Maintenance fee payment submitted in good faith on August 22, 2008 was in error.

In accordance with 37 C.F.R. § 1.28(c)(2)(ii), the following table itemizes the particular fee involved, the small entity fee amount actually paid (in good faith), the date on which the fee was paid, the large entity amount for the fee, the actual deficiency owed, and the total deficiency owed to the Office.


FEE INVOLVED	SMALL ENTITY FEE AMOUNT PAID	DATE ON WHICH FEE WAS PAID	LARGE ENTITY FEE	ACTUAL DEFICIENCY OWED
Maintenance Fee Due at 3.5 years	\$465	8/22/08	\$980	\$515
TOTAL DEFICIENCY OWED				\$515

Applicant : Michael W. Heartlein et al.
Serial No. : 09/753,385
Filed : January 3, 2001
Page : 2 of 2

Attorney's Docket No.: S2071-701642

The deficiency owed is being paid concurrently by way of Deposit Account authorization. Please apply any other charges or credits to Deposit Account No. 50-2762, referencing attorney docket no. S2071-701642.

Respectfully submitted,

By: 
Natalie A. Lissy, Reg. No. 59,651
LOWRIE, LANDO & ANASTASI, LLP
One Main Street
Cambridge, Massachusetts 02142
United States of America
Telephone: 617-395-7000
Facsimile: 617-395-7070

Docket No.: S2071-701642
Date: November 13, 2008

EXPRESS MAIL LABEL: EV 307784898 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 24 2008

Applicant : Michael W. Heartlein et al. Art Unit : 1646
Serial No. : 09/753,385 Examiner : Claire M. Kaufman
Filed : January 3, 2001 Confirmation No.: 2793
Patent No. : 6,858,578
Issue Date : February 22, 2005
Title : CHIMERIC PROTEINS FOR USE IN TRANSPORT OF A SELECTED
SUBSTANCE INTO CELLS


OFFICE OF PETITIONS

Commissioner for Patents

NOTIFICATION OF LOSS OF ENTITLEMENT TO SMALL ENTITY STATUS

Pursuant to 37 C.F.R. §§ 1.27(g)(2) and 1.33(b), I hereby notify the United States Patent & Trademark Office that this patent is no longer entitled to small entity status. Future maintenance fees will be paid as a non-small entity.

Rights in the above-referenced application have been assigned to Shire Human Genetic Therapies, Inc., as evidenced by assignments recorded at the United States Patent and Trademark Office on September 29, 1995 at Reel 7659, Frame 0770 and on August 31, 2006 at Reel 018224, Frame 0390. I hereby state that I am an agent authorized to act on behalf of Shire Human Genetic Therapies, Inc.


Printed name: KERRY A. FLYNN
Title: V.P. INTELLECTUAL PROPERTY
Date: 26 Aug 2008

Docket No.: S2071-701642/10278-025004 (0101)